EUVIMEDEUVIMED entdecken
Systematische ÜbersichtMetaanalyseOpen Access · CC BY 4.0

Safety and efficacy of glucagon-like peptide-1 receptor agonists among kidney transplant recipients: a systematic review and meta-analysis

Pajaree Krisanapan, Supawadee Suppadungsuk, Kanokporn Sanpawithayakul iD, Charat Thongprayoon, Pattharawin Pattharanitima, Supawit Tangpanithandee, Michael A Mao, Jing Miao, Wisit Cheungpasitporn iD

Clinical Kidney Journal · 01.02.2024 · 17 (2)

DOI: 10.1093/ckj/sfae018 ↗

Kurz gefasst

Systematische Übersicht in der Zeitschrift Clinical Kidney Journal, online erschienen am 02.02.2024. Verfasst von Pajaree Krisanapan und 8 weiteren Autor:innen. Beteiligte Einrichtung: Division of Nephrology and Hypertension, Department of Medicine, Mayo Clinic, Rochester, MN, USA. Die Arbeit wurde bisher 45-mal zitiert (Crossref) und nennt 61 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Evidence supporting glucagon-like peptide-1 receptor agonists (GLP-1RAs) in kidney transplant recipients (KTRs) remains scarce. This systematic review and meta-analysis aims to evaluate the safety and efficacy of GLP-1RAs in this population.

Methods

A comprehensive literature search was conducted in the MEDLINE, Embase and Cochrane databases from inception through May 2023. Clinical trials and observational studies that reported on the safety or efficacy outcomes of GLP-1RAs in adult KTRs were included. Kidney graft function, glycaemic and metabolic parameters, weight, cardiovascular outcomes and adverse events were evaluated. Outcome measures used for analysis included pooled odds ratios (ORs) with 95% confidence intervals (CIs) for dichotomous outcomes and standardized mean difference (SMD) or mean difference (MD) with 95% CI for continuous outcomes. The protocol was registered in the International Prospective Register of Systematic Reviews (CRD 42023426190).

Results

Nine cohort studies with a total of 338 KTRs were included. The median follow-up was 12 months (interquartile range 6–23). While treatment with GLP-1RAs did not yield a significant change in estimated glomerular filtration rate [SMD −0.07 ml/min/1.73 m2 (95% CI −0.64–0.50)] or creatinine [SMD −0.08 mg/dl (95% CI −0.44–0.28)], they were associated with a significant decrease in urine protein:creatinine ratio [SMD −0.47 (95% CI −0.77 to −0.18)] and haemoglobin A1c levels [MD −0.85% (95% CI −1.41 to −0.28)]. Total daily insulin dose, weight and body mass index also decreased significantly. Tacrolimus levels remained stable [MD −0.43 ng/ml (95% CI −0.99 to 0.13)]. Side effects were primarily nausea and vomiting (17.6%), diarrhoea (7.6%) and injection site pain (5.4%).

Conclusions

GLP-1RAs are effective in reducing proteinuria, improving glycaemic control and supporting weight loss in KTRs, without altering tacrolimus levels. Gastrointestinal symptoms are the main side effects.

Schlagwörter

Stichwörter der Autor:innen

GLP-1RAsType 2 diabetes mellitus (T2DM)glucagon-like peptide-1 receptor agonistkidney transplantationpost-transplant diabetes mellitus (PTDM)

Autor:innen und Institutionen

  • Division of Nephrology and Hypertension, Department of Medicine, Mayo Clinic, Rochester, MN, USA.
  • Division of Nephrology, Department of Internal Medicine, Faculty of Medicine, Thammasat University, Pathum Thani, Thailand.
  • Division of Nephrology, Department of Internal Medicine, Thammasat University Hospital, Pathum Thani, Thailand.
  • Chakri Naruebodindra Medical Institute, Faculty of Medicine Ramathibodi Hospital, Mahidol University, Samut PrakanThailand.
  • Division of Endocrinology and Metabolism, Department of Internal Medicine, Faculty of Medicine, Thammasat University, Pathum Thani, Thailand.
  • Department of Clinical Epidemiology, Faculty of Medicine, Thammasat University, Pathum Thani, Thailand.

ORCID-Profile: Kanokporn Sanpawithayakul, Wisit Cheungpasitporn

Zitieren

APA

Krisanapan, P., Suppadungsuk, S., Sanpawithayakul, K., Thongprayoon, C., Pattharanitima, P., Tangpanithandee, S., Mao, M. A., Miao, J., & Cheungpasitporn, W. (2024). Safety and efficacy of glucagon-like peptide-1 receptor agonists among kidney transplant recipients: a systematic review and meta-analysis. Clinical Kidney Journal, 17(2). https://doi.org/10.1093/ckj/sfae018

Vancouver

Krisanapan P, Suppadungsuk S, Sanpawithayakul K, Thongprayoon C, Pattharanitima P, Tangpanithandee S, et al. Safety and efficacy of glucagon-like peptide-1 receptor agonists among kidney transplant recipients: a systematic review and meta-analysis. Clinical Kidney Journal. 2024;17(2). doi:10.1093/ckj/sfae018

BibTeX
@article{Krisanapan2024,
  author = {Krisanapan, Pajaree and Suppadungsuk, Supawadee and Sanpawithayakul, Kanokporn and Thongprayoon, Charat and Pattharanitima, Pattharawin and Tangpanithandee, Supawit and Mao, Michael A and Miao, Jing and Cheungpasitporn, Wisit},
  title = {Safety and efficacy of glucagon-like peptide-1 receptor agonists among kidney transplant recipients: a systematic review and meta-analysis},
  journal = {Clinical Kidney Journal},
  year = {2024},
  volume = {17},
  number = {2},
  doi = {10.1093/ckj/sfae018}
}
Kostenlos starten →